|
1
|
Cox V, Brigden G, Crespo RH, Lessem E, Lynch S, Rich ML, Waning B, Furin J. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2018; 22:407-412. [DOI: 10.5588/ijtld.17.0706] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- V. Cox
- Drug-Resistant TB Scale-Up Treatment Action Team, Global Drug-Resistant Tuberculosis Initiative, Stop TB Partnership, Geneva, Switzerland, Center for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University
of Cape Town, Cape Town, South Africa
| | - G. Brigden
- International Union Against Tuberculosis and Lung Disease, Geneva
| | - R. H. Crespo
- Global Drug Facility, Stop TB Partnership, Geneva, Switzerland
| | - E. Lessem
- Treatment Action Group, New York, New York
| | - S. Lynch
- Médecins Sans Frontières Access Campaign, New York, New York
| | - M. L. Rich
- Partners In Health, Boston, Massachusetts, Brigham and Women's Hospital, Boston, Massachusetts
| | - B. Waning
- Global Drug Facility, Stop TB Partnership, Geneva, Switzerland
| | - J. Furin
- Partners In Health, Boston, Massachusetts, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|